Abstract
Manufacturers use standards as the basis for demonstrating the safety of their devices in the preclinical phase. However, standardization issues arise because of simplifications that have to be made to improve comparability and repeatability, compared to the complex in vivo conditions. Specific aspects of standardization deserve rigorous analysis, and standards need to be continuously questioned in order to have clinically relevant and predictive results.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
